Luciole Pharmaceuticals

Luciole Pharmaceuticals is pioneering a novel therapeutic approach centered on mitochondrial DNA repair. The company is developing small molecule activators of the OGG1 enzyme, aiming to enhance the base excision repair pathway to correct oxidative damage to mtDNA, thereby addressing mitochondrial dysfunction and the associated inflammatory cascade. Its strategy targets the root cause of several age-related neurodegenerative diseases. The company leverages a virtual model and is led by a team with deep expertise in mitochondrial biology, drug discovery, and development.

Discovery and development of small molecule activators of the OGG1 enzyme to accelerate base excision repair (BER) of oxidative damage in mitochondrial DNA.

Luciole operates in the growing mitochondrial therapeutics space, competing with companies targeting mitochondrial biogenesis, quality control (mitophagy), and antioxidant pathways. Its specific focus on OGG1 activation for mtDNA repair is a unique and differentiated mechanism, but it will compete for funding and partnerships within the broader neurology and mitochondrial medicine fields.